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Abstract
Anemia during pregnancy and the postpartum period is commonly caused by iron deficiency and is a
significant worldwide issue with severe consequences for both mother and developing fetus. From a
worldwide perspective, iron-deficiency anemia (IDA) during pregnancy is highest in the Asia-Pacific
region; however, there has been little guidance in this region for safe and effective treatment. An expert
panel was convened to develop a concise and informative set of recommendations for the treatment of
IDA in pregnant and postpartum women in the Asia-Pacific region. This manuscript provides these
recommendations and aims to reduce the morbidity and mortality associated with IDA in pregnant and
postpartum women in the Asia-Pacific region. The consensus recommendations define anemia as a
hemoglobin (Hb) level <10.5 g/dL during pregnancy and <10 g/dL during the postpartum period, and
provide cut-off Hb levels to initiate therapy with oral iron, intravenous iron or red blood cell transfusion.
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Abstract  
Anemia during pregnancy and the postpartum period is commonly caused by 
iron deficiency and is a significant worldwide issue with severe consequences 
for both mother and developing fetus. From a worldwide perspective, iron-
deficiency anemia (IDA) during pregnancy is highest in the Asia-Pacific 
region; however there has been little guidance in this region for safe and 
effective treatment. An expert panel was convened to develop a concise and 
informative set of recommendations for the treatment of IDA in pregnant and 
postpartum women in the Asia-Pacific region. This manuscript provides these 
recommendations and aims to reduce the morbidity and mortality associated 
with IDA in pregnant and postpartum women in the Asia-Pacific region. The 
consensus recommendations define anemia as a hemoglobin (Hb) level <10.5 
g/dL during pregnancy and <10 g/dL during the postpartum period, and 
provide cut-off Hb levels to initiate therapy with oral iron, intravenous iron or 
red blood cell transfusion.  
 
 3 
Introduction 
Anemia is one of the most prevalent diseases worldwide, affecting 24.8% of 
the human population (1.62 billion people) (Table 1), and is a major health 
concern [3,29]. Iron shortage is the single most common nutritional deficit in 
the world [3,12] and is the major cause of anemia, accounting for 
approximately 50% of cases [28,29]. The prevalence of iron-deficiency 
anemia (IDA) varies among countries but is a particular problem in the 
developing world, reflecting differences in race, socio-economic factors, 
nutritional habits, medical care and the frequency of parasitic illnesses [12]. 
Numerous countries conduct interventions to reduce anemia, particularly in 
susceptible groups such as pregnant women and young children.  
 
Insert Table 1 near here 
 
Anemia during pregnancy is a significant concern with the World Health 
Organization (WHO) estimating a prevalence of 41.8% amongst pregnant 
women (Table 1) [29]. Iron demand increases rapidly in the second and third 
trimester of pregnancy with the needs of the developing fetus, with a daily 
requirement of up to 10 mg [21]. Iron absorption from the diet also increases 
during pregnancy through upregulation of iron transporters in the gut [19]; 
however, this increase in absorption is not sufficient to meet the demand 
during the latter stages of pregnancy. Therefore, iron balance depends largely 
upon maternal iron stores [9,12]. A pre-pregnancy store of more than 500 mg 
of iron is required to avoid iron deficiency during pregnancy, yet such 
adequate levels of iron are only present in 20% of menstruating women before 
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pregnancy ensues [3]. These iron store deficits are exacerbated by the blood 
loss experienced during the delivery process and add to the considerable risk 
of developing postpartum anemia [9]. 
 
The consequences of IDA during pregnancy are often serious and long lasting 
for both the mother and fetus [12,22] (Table 2). Expectant mothers with 
anemia often experience increased fatigue levels, reduced exercise 
performance and reduced mental performance [12,22]. Furthermore, severe 
anemia (hemoglobin [Hb] <9 g/dL) is related to an increased risk of 
prematurity, small for gestational-age babies and spontaneous abortion [12]. 
Fetal iron metabolism is completely dependent upon maternal iron delivery via 
the placenta; therefore, the effects of anemia on the fetus are related to the 
extent of maternal iron deficiency with increased mortality linked to severe IDA 
[12]. Considerable efforts to decrease the prevalence of IDA during pregnancy 
through preventative methods have been largely unsuccessful, and access to 
new therapies such as intravenous (i.v.) iron and erythropoiesis-stimulating 
agents (ESAs), readily available in the USA or Europe, can be limited in 
settings where resources are scarce and guidance is negligible. 
 
Insert Table 2 near here  
 
Currently, there are three main options for the treatment of IDA: oral iron, i.v. 
iron and red blood cell transfusion. ESAs can also be used to treat anemia in 
some situations [11]. Recent recommendations, published in Europe and 
North America, include oral iron for the treatment of mild-to-moderate IDA 
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during pregnancy with i.v. iron suggested for those unresponsive to oral 
treatment [20] (Table 3). The high costs associated with therapies such as 
ESAs often prevent their use in some of the world’s developing regions where 
anemia is most common.  
 
Insert Table 3 near here  
Treatment of IDA arising during pregnancy and the postpartum period 
Oral iron 
Oral iron, administered in the form of ferrous sulphate, ferrous fumerate, 
ferrous gluconate or iron hydroxide polymaltose complex, is considered the 
current standard in the treatment of IDA and is most commonly prescribed in 
cases of mild-to-moderate anemia [9,12]. Benefits of oral iron intervention 
include ease of use with no medical expertise required for administration. 
However, limited efficacy and low patient compliance are often an issue, 
particularly due to gastrointestinal side effects [18,20]. As such, oral 
administration of iron may take a long time to correct IDA. Moreover, among 
the different oral iron preparations, ferrous salts, but not a polysaccharide-
ferric iron complex lead to oxidative stress as evidenced by increased levels 
of non-transferrin bound iron (or NTBI) [14]. 
 
I.v. iron 
The use of i.v. iron to treat IDA in pregnant women was first examined almost 
60 years ago; enhanced Hb levels following i.v. iron sucrose administration 
were demonstrated while iron not utilized by the hematopoietic tissues helped 
replenish maternal iron stores [17]. More recent studies have demonstrated i.v. 
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iron to be more efficient than oral iron at increasing Hb levels and replenishing 
iron stores [1,4,6]. The recently published recommendations for the treatment 
of IDA in pregnancy include i.v. iron as an effective alternative to oral iron 
during the second and third trimester for pregnant women who fail to respond 
to oral iron therapy [7] (Table 3).  
 
I.v. iron preparations include iron sucrose, sodium ferric gluconate, low 
molecular weight iron dextran and newer ‘next generation’ preparations such 
as ferric carboxymaltose [7]; however, these preparations have substantially 
different safety profiles [2]. For example, dextran-containing i.v. iron 
preparations have been shown to be associated with an increased risk of 
anaphylactic reactions [2], whilst iron sucrose and sodium ferric gluconate are 
associated with fewer side effects [2]. Furthermore, subtle structural variations 
between the iron sucrose formulations produced by different manufacturers 
may affect the stability of the iron complex and, in turn, the safety and efficacy 
profile [26]. 
 
Additionally, numerous studies have demonstrated the efficacy and safety of 
i.v. iron sucrose in pregnant (second and third trimester) [1,10] and 
postpartum women [6,7]. Experience with i.v. iron sucrose in the Asia-Pacific 
region is growing [16,24,27] and data are comparable to results from 
European studies [6,10], demonstrating that i.v. iron sucrose is effective, 
provides rapid correction of anemia and is well tolerated in treating IDA during 
pregnancy [16,24,27].  
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Packed cells or red blood cell transfusion 
Although blood transfusions are an effective treatment for IDA, since they 
deliver exactly what the body needs (red blood cells) without any further 
physiological effort, they do not correct the underlying cause of anemia. 
Furthermore, there are many inherent risks involved with this treatment, 
including serious infection, incorrect transfusion, negative impact on the 
immune system and transfusion reactions [11,13]. Additionally, certain groups 
of the population may refuse blood transfusions due to religious beliefs, and 
limited blood supply often means that stock is reserved for emergencies. 
Therefore, the administration of a blood transfusion should be considered as a 
last resort when a patient is unresponsive to i.v. iron supplementation or is in 
a critical condition. 
 
Managing IDA in pregnant and postpartum women in the Asia-Pacific 
region – present situation 
The prevalence of anemia during pregnancy and the postpartum period in the 
Asia-Pacific region is the highest worldwide and comprises a particular 
problem. In Southeast Asia and the Western Pacific, 48.2% and 30.7% of 
pregnant women have anemia, but some data indicate that prevalence could 
be as high as 85.6% and 90.2%, respectively [29] (Table 4). In this region, 
oral iron and blood transfusions are currently the most common therapies for 
the treatment of IDA (Table 5). However, these strategies are suboptimal 
since oral iron is slow to increase Hb to desired levels in moderate-to-severe 
anemia. Moreover, a limited availability of blood donors, high costs and risk of 
infection means that blood transfusions should only be used sparingly in very 
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serious cases [11,13]. It is, therefore, vital that effective guidelines for the 
treatment of IDA in pregnancy are developed for the Asia-Pacific region to 
ensure prompt intervention and optimal care of the mother and developing 
fetus.  
 
Insert Table 4 near here  
Insert Table 5 near here 
 
Physicians throughout the Asia-Pacific region face a range of unique 
challenges when managing IDA in pregnant and postpartum women (Table 6). 
In some areas, testing for and treatment of anemia during pregnancy are not a 
priority since there is an acceptance that anemia is commonplace in the 
general population accompanied by a lack of perception of the consequences 
of maternal IDA. Also, the high prevalence of thalassemia and malaria in 
some regions complicates diagnosis and treatment; therefore, identifying the 
cause of anemia is essential before intervention is initiated. Access to the 
appropriate therapy is often an issue with geographic and economic barriers, 
preventing optimal care of patients in greatest need.  
 
Evidence of the efficacy and safety of i.v. iron as a treatment for IDA is 
growing through a number of international trials [1,4,6,7,10,15,16]. These 
studies have shown a rapid correction of anemia and a reduced risk of blood 
transfusions in the peripartum and postpartum period. As a result, the use of 
i.v. iron as a treatment for IDA has increased in Europe in the 
obstetric/gynecologic setting. Similar studies at the local level in the Asia-
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Pacific region have been lacking and consequently the use of i.v. iron in this 
region has been limited. Other issues including fear of adverse events, 
availability of resources and economic viability (Table 6) also restrict the use 
of i.v. iron in these communities. However, intervention with i.v. iron is 
expected to grow in the Asia-Pacific region in parallel with evidence from 
recent trials conducted in this section of the population [16,24,27].  
 
[Insert Table 6 near here] 
 
Recommendations for diagnosis and treatment of IDA in pregnancy in 
the Asia-Pacific region 
Accepted guidelines to assist physicians treating pregnant women with IDA 
are lacking in the Asia-Pacific region. An expert panel (Appendix), of 
physicians involved in the treatment of anemia in the obstetrics/gynecology 
setting and with long-term experience of iron therapy, was convened to 
develop a concise and informative set of recommendations for the treatment 
of IDA in pregnant and postpartum women in the Asia-Pacific region. This 
manuscript provides these recommendations and aims to raise awareness of 
the safety and efficacy of treatments available for IDA to meet the 
requirements of pregnant and postpartum women in the Asia-Pacific region. 
 
1. Diagnosis of IDA during pregnancy in the Asia-Pacific region 
Anemia in pregnancy is defined by the Center for Disease Control and 
Prevention as an Hb level of below 11 g/dL in the first and third trimester and 
an Hb below 10.5 g/dL in the second trimester [23]; likewise, WHO define 
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anemia in pregnancy as an Hb level of below or equal to 11 g/dL [29]. The Hb 
cut-off levels currently used in practice are often lower than these levels 
(Table 5); hence it is important to raise awareness of the criteria used for the 
diagnosis of anemia in pregnant women. A hematologic profile, including Hb 
levels and hematocrit, enables the diagnosis of anemia [12] and biochemical 
markers of iron levels are important for determining the cause of anemia 
before treatment is initiated. To identify IDA, both Hb (an indicator of anemia) 
and serum ferritin (an indicator of iron storage) should be assessed: low 
ferritin levels indicate iron deficiency, while normal-to-high ferritin levels can 
indicate thalassemia, lead poisoning and inflammation [25]. Therefore, the 
appropriate use of markers for iron levels should be established to aid the 
diagnosis of IDA during pregnancy and the postpartum period.  
 
Consensus recommendations for diagnosis of IDA  
during pregnancy in the Asia-Pacific region 
 
 Hb <10.5 g/dL 
 Ferritin <20 µg/L 
 If ferritin >20 µg/L, other causes of anemia such as thalassemia and vitamin 
B12 deficiency should be excluded 
o Consider C-reactive protein assessment to rule out underlying infection 
(causes elevated ferritin levels) 
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Consensus recommendations for diagnosis of IDA 
during the postpartum period in the Asia-Pacific region 
 
 Hb <10 g/dL 
 Ferritin measurement is not recommended in the early postpartum period since 
it can be normal or elevated due to inflammation 
 Treatment can commence once: 
o The cardiovascular system is stable  
o There is no ongoing bleeding 
 
2. Treatment of IDA in pregnancy and the postpartum period in the  
Asia-Pacific region 
Due to the serious consequences of IDA in pregnancy, prompt and effective 
intervention is required (Tables 2 and 3). It is important to note that i.v. iron 
and oral iron are only licensed for the treatment of iron deficiency. 
Furthermore, the use of i.v. iron is contraindicated during the first trimester of 
pregnancy. However, the use of i.v. iron is considered safe in the second and 
third trimester [20]. It is, therefore, advisable to check the labels for both oral 
and i.v. iron compounds prior to their administration. The consensus 
recommendations (Figures 1 and 2) target the application of oral iron, i.v. iron 
and blood transfusion to specific severities of IDA (stratified by Hb level) to 
ensure the safest and most efficient treatment possible. The Hb cut-off values 
were agreed by the expert panel to indicate the need for treatment of IDA 
during pregnancy (Figure 1) and the postpartum period (Figure 2). 
 
[Insert Figure 1 near here] 
[Insert Figure 2 near here] 
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Areas requiring further consideration 
Recent studies have demonstrated the efficacy and safety of i.v. iron in 
pregnant (second and third trimester) [1,4,10] and postpartum women [6,10]. 
Experience with i.v. iron in the Asia-Pacific region is growing [16,24,27]. 
However, further studies in this region are warranted to enhance confidence in 
the use of i.v. iron among prescribing physicians. Measures to raise 
awareness of the consequences of IDA are also required to ensure the 
appropriate testing and prompt treatment of anemia during pregnancy and the 
postpartum period.  
 
Conclusions 
IDA is the most frequent form of anemia in pregnancy and can have serious 
consequences for both the mother and fetus. The majority of women do not 
have adequate iron stores to meet the dramatic increase in requirements 
during the second and third trimester of pregnancy. From a worldwide 
perspective, IDA in pregnancy is highest in the Asia-Pacific region; however, 
there has been little guidance in this region for the safe and effective 
treatment of IDA during pregnancy and the postpartum period. Currently, the 
main interventions in this region are oral iron and blood transfusions. However, 
i.v. iron is more effective, provides more rapid Hb correction, corrects iron 
stores and is better tolerated than oral iron in treating IDA during pregnancy 
[1,4,7]. Furthermore, recent studies have demonstrated the efficacy and 
safety of i.v. iron in the second and third trimester of pregnancy [1,4,7] and in 
postpartum women [6,7]. The goal of the recommendations presented here is 
 13 
to reduce the morbidity and mortality associated with IDA in pregnant and 
postpartum women in the Asia-Pacific region. Consensus recommendations 
include a definition of anemia as an Hb level below 10.5 g/dL in pregnancy 
and below 10 g/dL in the postpartum period. The panel also advocates the 
use of i.v. iron in the second and third trimester of pregnancy to correct 
anemia and reduce the risk of transfusion in the postpartum period. Further 
randomized phase III trials with i.v. iron in the Asia-Pacific region are 
warranted to optimize clinical outcomes for the mother and developing fetus.  
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Figure legends 
 
Figure 1 – Consensus recommendations for the treatment of IDA during 
pregnancy in the Asia-Pacific region 
 
 
Figure 2 – Consensus recommendations for the treatment of IDA during the 
postpartum period in the Asia-Pacific region 
  
 
Table 1 – Worldwide estimated prevalence of anemia [29] 
 
 
Population group 
 
 
Prevalence (%) 
 
Pre-school-age children 
School-age children 
Pregnant women 
Non-pregnant women 
Men 
Elderly 
Total population 
 
47.4 
25.4 
41.8 
30.2 
12.7 
23.9 
24.8 
Reproduced with permission from the World Health Organization 
 
 
Table 1
Table 2 – Consequences of IDA during pregnancy and postpartum 
[9,12,20,22] 
 
Mother 
 
Fetus 
 
 Fatigue 
 Increased risk for blood 
transfusion 
 Reduced physical performance 
 Reduced mental performance 
 Infection 
 Risk of hospitalization 
 Inhibited lactation 
 Postpartum depression:  
‘baby blues’ 
 
 Increased mortality 
 Reduced birth weight 
 Increased preterm birth 
 Growth retardation 
 Neurologic impairment 
 Impaired placental growth 
 
 
Table 2
Table 3 – Guidelines for the treatment of IDA during pregnancy [5,8,20] 
 
Swiss Society of Obstetrics  
and Gynaecology 
The Network for Advancement of 
Transfusion Alternatives (NATA) 
Pregnancy 
 Oral iron in patients with  
mild-to-moderate IDA (9–10.5 g/dL) 
 I.v. iron in second and third 
trimester in patients: 
o Unresponsive to oral iron 
o With severe IDA (<9 g/dL) 
o With other factors such as 
requirement for rapid repletion 
(Jehovah’s Witnesses etc) 
 Oral iron in first and second 
trimester 
 Consider i.v. iron after 14 weeks’ 
gestation in patients unresponsive to 
oral iron (Hb increase <0.5 g/dL in  
2 weeks) 
 I.v. iron in third trimester in case of 
IDA 
Postpartum 
 Oral iron in patients with mild 
anemia (9.5–12 g/dL) 
 I.v. iron in moderate-to-severe 
anemia (8.5–9.5 g/dL) 
o Consider ESAs if Hb <8 g/dL 
 Consider transfusion if Hb <6 g/dL 
 Without ongoing bleeding 
 I.v. iron if Hb 6–9.5 g/dL 
o ESA can be used in  
non-responders 
 Consider transfusion if Hb <6 g/dL 
IDA, iron-deficiency anemia; i.v., intravenous; ESA, erythropoiesis-stimulating 
agent; Hb, hemoglobin 
 
Table 3
 Table 4 – Estimated prevalence of anemia in pregnant women  
(1993–2005) [29] 
WHO region Prevalence of anemia 
in pregnant women 
(%) 
[95% CI] 
Number of pregnant 
women affected 
(millions) [95% CI] 
Africa 57.1 [52.8–61.3] 17.2 [15.9–18.5] 
Americas 24.1 [17.3–30.8] 3.9 [2.8–5.0] 
Southeast Asia 48.2 [43.9–52.5] 18.1 [16.4–19.7] 
Europe 25.1 [18.6–31.6] 2.6 [2.0–3.3] 
Eastern Mediterranean 44.2 [38.2–50.3] 7.1 [6.1–8.0] 
Western Pacific 30.7 [28.8–32.7] 7.6 [7.1–8.1] 
Global 41.8 [39.9–43.8] 56.4 [53.8–59.1] 
Reproduced with permission from the World Health Organization 
CI, confidence interval; WHO, World Health Organization 
 
 
Table 4
Table 5 – Overview of treatment practice according to the panel members 
Country Average 
patient 
age 
(year) 
Prevalence of 
IDA  
Country-specific 
guidelines? 
Hb cut-offs for treatment 
(based on available guidelines or own 
practice experience) 
Bangladesh 25 50% pregnancy 
50% postpartum 
Institute of Public 
Health and Nutrition 
(IPHN)  
2002 (oral iron and  
blood transfusion) 
First trimester 
 >10 g/dL (oral iron) 
 <10 g/dL (i.v. iron)  
Second and third trimester 
 <9 g/dL (i.v. iron) 
 <8 g/dL (blood transfusion) 
 
China 28–30 6% pregnancy 
7% postpartum 
Yes (oral iron, i.v. iron 
and blood 
transfusions) 
First trimester  
 >10 g/dL (oral iron) 
Second and third trimester 
 <9 g/dL (oral iron) 
 <7 g/dL (i.v. iron) 
 <8 g/dL before delivery (blood 
transfusion) 
 
Indonesia 8–48 67% pregnancy 
72% postpartum 
Yes (oral iron, i.v. 
iron) 
Second and third trimester 
 <10 g/dL (i.v. iron) 
 <7 g/dL (blood transfusion) 
 
Table 5
Pakistan 22–34 88% pregnancy 
Postpartum: no 
data 
 
 
None 7–9 g/dL  
 14–36 weeks (i.v. iron) 
 >36 weeks (blood transfusion) 
6–7 g/dL  
 Asymptomatic (i.v. iron) 
 Symptomatic (blood transfusion) 
<6 g/dL 
 Blood transfusion 
Philippines 35 44% pregnancy 
43% postpartum 
None  >8 g/dL oral iron 
 <8 g/dL blood transfusion 
 Avoid blood transfusion if possible 
Singapore 25–30 10–24% 
pregnancy 
Postpartum: no 
data 
None First to third trimester  
 8–11 g/dL (oral iron/i.v. iron) 
 <8 g/dL (blood transfusion)  
 
Thailand 25–30 10–24% 
pregnancy 
Postpartum: no 
data 
None First and third trimester  
 7–11 g/dL (oral iron) 
 <7 g/dL (blood transfusion)  
Second trimester 
 7–10.5 g/dL (oral iron) 
 <7 g/dL (blood transfusion) 
 
Vietnam 15–50 32% pregnancy 
Postpartum: no 
data 
None  ≥8 g/dL oral iron + folate 
 <8 g/dL blood transfusion + folate 
 
IDA, iron-deficiency anemia; Hb, haemoglobin; i.v., intravenous 
Table 6 – Overview of key treatment issues for the Asia-Pacific region  
Education  In some areas, testing for anemia is not seen as a priority  
since severe anemia is not perceived as a major problem 
 Issues surrounding the prescription of oral iron and blood 
transfusions based on empirical rather than evidence-
based experience 
 Patients avoid injections which means that physicians have 
less experience in giving them 
 Fear of iron-dextran anaphylaxis from previous trials 
 Physicians are unaware of the difference between i.v. iron 
dextran and i.v. iron sucrose 
 Lack of information on i.v. iron use 
 Lack of guidelines for the use of i.v. iron in pregnancy 
Cause of 
anemia 
 Factors other than iron deficiency can cause anemia 
 Thalassemia is prevalent in the Asia-Pacific region 
Diet  Low iron diet compared with Europe and North America 
 Socio-economic background can result in greater risk of  
iron deficiency 
Transfusions  Infection risk (HIV, hepatitis B and C) [11,24] 
 Shortage of available blood 
 Cost 
Cost of i.v. 
iron 
 Governments may not finance treatment 
 Where governments do not fund treatments, patients 
cannot afford i.v. iron themselves  
Accessibility  Many patients do not have easy access to medical care 
 Difficult to get patient to travel to see physician or get 
medication to patient 
 Large hospitals have good facilities but many deprived 
areas have poor facilities 
i.v., intravenous; HIV, human immunodeficiency virus 
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